Advertisement

Topics

Aspirin for Primary Cardiovascular Prevention: Assessing the Pros and Cons

07:20 EDT 12 Jul 2019 | NEJM

Estimates from a meta-analysis suggest that the risks outweigh the benefits for most primary prevention patients.

Original Article: Aspirin for Primary Cardiovascular Prevention: Assessing the Pros and Cons

NEXT ARTICLE

More From BioPortfolio on "Aspirin for Primary Cardiovascular Prevention: Assessing the Pros and Cons"

Advertisement
Quick Search
Advertisement
Advertisement